Español 药物安全通讯 Drug Safety Podcasts The FDA Drug Safety Communications posted on this web page are intended to provide important information to patients and health care professionals about […]

Between April 25, 2017, and July 6, 2023, FDA identified 209 cases worldwide (197 domestic) of pruritus after stopping treatment with cetirizine (n=180), levocetirizine (n=27), or […]

On May 15, 2025, the Food and Drug Administration approved retifanlimab-dlwr (Zynyz, Incyte Corporation) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable […]

Opioid addiction and abuse is an immense public health crisis and addressing it is one of the FDA’s highest priorities. In 2019, an average of 38 […]

Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Reference #: 25-HFD-45-04-01 Product: Drugs Recipient: Nana Barseghian, M.D. 19875 Nordhoff StreetNorthridge, CA 91324United States Issuing Office: […]

The Food and Drug Administration is advising consumers not to purchase or use Umovy, a product promoted and sold for joint pain on various websites, including […]

The Food and Drug Administration is advising consumers not to purchase or use Unavy, a product promoted and sold for joint pain on various websites, including […]

Exceptions or additions to the recognized standards For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time: Anaerobes Content current as […]

FDA has reevaluated data supporting amoxicillin/clavulanate breakpoints against Haemophilus influenzae. The review included a publication describing the Clinical and Laboratory Standards Institute (CLSI) rationale for revision […]